Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I.
Raquel VieiraSelma B SoutoElena Sánchez-LopezAna López MachadoPatricia SeverinoSajan JoseAntonello SantiniAna FortunaMaria Luisa GarcíaAmélia M SilvaEliana Barbosa SoutoPublished in: Pharmaceuticals (Basel, Switzerland) (2019)
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.
Keyphrases
- glycemic control
- type diabetes
- metabolic syndrome
- blood glucose
- insulin resistance
- weight loss
- end stage renal disease
- ejection fraction
- ms ms
- randomized controlled trial
- newly diagnosed
- adipose tissue
- mass spectrometry
- chronic kidney disease
- uric acid
- systematic review
- prognostic factors
- early onset
- cardiovascular disease
- skeletal muscle
- patient reported outcomes
- fatty acid
- combination therapy
- replacement therapy
- patient reported